JSL S.A. (BVMF:JSLG3)

CTI BioPharma Balance Sheet

Financials in millions BRL. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	326.99	442.82	610.87	475.63	152.95	64.58
Short-Term Investments	1,421	1,451	1,243	397.59	801.48	573.87
Cash & Short-Term Investments	1,748	1,894	1,854	873.21	954.43	638.44
Cash Growth	-53.03%	2.16%	112.34%	-8.51%	49.49%	-88.94%
Accounts Receivable	1,900	1,815	1,583	1,160	1,283	856.56
Other Receivables	216.82	187	162.27	190.04	277.73	272.42
Receivables	2,117	2,002	1,745	1,350	1,560	1,129
Inventory	97.85	97.19	64.84	57.64	55.88	44.85
Prepaid Expenses	69.52	37.79	28.57	25.42	20.41	14.76
Other Current Assets	647.76	587.58	286.5	99.94	63.47	73.39
Total Current Assets	4,679	4,619	3,979	2,406	2,655	1,900
Property, Plant & Equipment	6,078	6,058	5,755	4,348	3,013	1,812
Long-Term Investments	0.92	0.76	-	0.01	0.57	0.78
Goodwill	610.83	610.83	610.83	596.33	571.73	519.72
Other Intangible Assets	286.21	297.29	335.25	275.35	274.01	236.74
Long-Term Accounts Receivable	32.22	25.3	36.02	20.1	14.33	13.79
Long-Term Deferred Tax Assets	290.17	164.28	127.43	91.77	35.58	37.34
Other Long-Term Assets	606.2	705.06	1,046	504.65	558.09	318.27
Total Assets	12,584	12,480	11,889	8,242	7,122	4,839
Accounts Payable	293.72	311.79	498.31	642.26	370.9	136.58
Accrued Expenses	569.8	549.2	459.78	455.61	348.16	204.43
Short-Term Debt	-	-	-	-	-	2.04
Current Portion of Long-Term Debt	1,470	1,512	953.3	323	74.27	277
Current Portion of Leases	187.65	154.75	165.33	88.69	96.87	52.93
Current Income Taxes Payable	2.25	1.64	3.44	5.33	20.29	5.94
Other Current Liabilities	372.4	478.97	287.03	243.51	301.28	266.72
Total Current Liabilities	2,896	3,008	2,367	1,758	1,212	945.64
Long-Term Debt	5,937	5,821	5,867	3,918	3,515	2,049
Long-Term Leases	616.8	512.32	463.48	409.35	260.76	218.47
Long-Term Deferred Tax Liabilities	240.82	259.9	171.65	121.68	116.91	92.56
Other Long-Term Liabilities	1,102	1,108	1,356	622.4	688.09	467.47
Total Liabilities	10,792	10,710	10,225	6,830	5,792	3,774
Common Stock	806.69	806.69	806.69	806.69	806.69	767.23
Retained Earnings	1,007	975.3	887.66	626.04	534.25	334.78
Treasury Stock	-43.09	-42.58	-42.26	-42.21	-40.7	-40.7
Comprehensive Income & Other	20.38	30.95	11.35	23.19	29.61	2.01
Total Common Equity	1,791	1,770	1,663	1,414	1,330	1,063
Minority Interest	-	-	-	-1.1	-	1.83
Shareholders' Equity	1,791	1,770	1,663	1,413	1,330	1,065
Total Liabilities & Equity	12,584	12,480	11,889	8,242	7,122	4,839
Total Debt	8,212	8,000	7,449	4,739	3,947	2,600
Net Cash (Debt)	-6,464	-6,106	-5,595	-3,866	-2,992	-1,961
Net Cash Per Share	-22.72	-21.46	-19.66	-18.14	-14.03	-9.26
Filing Date Shares Outstanding	284.42	284.51	284.54	284.53	284.73	278.29
Total Common Shares Outstanding	284.42	284.51	284.54	284.53	284.73	278.29
Working Capital	1,783	1,610	1,612	647.75	1,443	954.79
Book Value Per Share	6.30	6.22	5.85	4.97	4.67	3.82
Tangible Book Value	894.14	862.24	717.36	542.03	484.11	306.86
Tangible Book Value Per Share	3.14	3.03	2.52	1.91	1.70	1.10
Machinery	6,483	6,581	6,201	4,788	3,517	2,217
Construction In Progress	27.35	24.04	15.27	26.01	32.36	7.1
Leasehold Improvements	371.42	368.81	340.78	326.48	325.42	259.32

Source: S&P Global Market Intelligence. Standard template. Financial Sources.